Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 6 min ago
PreprintAll rights reservedbioRxiv

ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells

  • C. Faundez Vidiella
  • Y. Sfragano
  • I. Tusa
  • B. Stecca
  • S. Espinosa Gil1
  • J. M. Lizcano
  • E. Rovida
  1. 1Department of Biochemistry and Molecular Biology, Institute of Neuroscience, Universitat Autonoma de Barcelona. Protein Kinases in Cancer Research (VHIR). Depar
Read full textPDFDOICite

Related

  1. IKKα and IKKβ serve as kinase-independent scaffolds that prevent proteasomal degradation of NEMO
    S. J. Cook, K. Balmanno, J. A. Prescott +3
    bioRxivPreprintCC BYFull textOncologybioRxiv
  2. Cooperative inhibition of mTORC1 disrupts iron–redox homeostasis and triggers ferritinophagy-dependent ferroptosis in hepatocellular carcinoma
    Xinyu Chen, Zhen Tan, Shiqiao Zhao +11
    Redox BiologyPeer-reviewedCC BYFull textMolecular biology & gene regulationGeneral biologyDOAJ
  3. 601 GARP–TGF-β1 blockade with livmoniplimab reprograms spatial tumor niches and enhances PD-1 inhibition in human tumor explants
    Patrick Caplazi, Tolga Turan, Iraz Aydin +14
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. ID4 enhances ferroptosis sensitivity in gastric cancer by promoting ubiquitination degradation of GPX4.
    Fubo Jing, Wenshuai Zhu, He Qi +5
    Cellular and molecular life sciences : CMLSPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  5. FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.
    Zhou Shang, Changqing Jing, Jiyuan Liu +5
    BMC cancerPeer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@misc{vidiella2026erk5,
  title = {{ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells}},
  author = {C. Faundez Vidiella and Y. Sfragano and I. Tusa and B. Stecca and S. Espinosa Gil and J. M. Lizcano and E. Rovida},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.17.752291},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.17.752291v1},
}
RIS
TY  - UNPB
TI  - ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells
AU  - C. Faundez Vidiella
AU  - Y. Sfragano
AU  - I. Tusa
AU  - B. Stecca
AU  - S. Espinosa Gil
AU  - J. M. Lizcano
AU  - E. Rovida
PY  - 2026
DA  - 2026/09/17
PB  - bioRxiv
DO  - 10.64898/2026.09.17.752291
UR  - https://www.biorxiv.org/content/10.64898/2026.09.17.752291v1
ER  -